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Background: The optimal first-line treatment for intermittent claudication is currently unclear.
Objective: To compare the cost-effectiveness of endovascular revascularization vs supervised hospital-based exercise in
patients with intermittent claudication during a 12-month follow-up period.
Design: Randomized controlled trial with patient recruitment between September 2002-September 2006 and a 12-
month follow-up per patient.
Setting: A large community hospital.
Participants: Patients with symptoms of intermittent claudication due to an iliac or femoro-popliteal arterial lesion (293)
who fulfilled the inclusion criteria (151) were recruited. Excluded were, for example, patients with lesions unsuitable for
revascularization (iliac or femoropopliteal TASC-type D and some TASC type-B/C.
Intervention: Participants were randomly assigned to endovascular revascularization (76 patients) or supervised hospital-
based exercise (75 patients).
Measurements:Mean improvement of health-related quality-of-life and functional capacity over a 12-month period, cumula-
tive 12-month costs, and incremental costs per quality-adjusted life year (QALY) were assessed from the societal perspective.
Results: In the endovascular revascularization group, 73% (55 patients) had iliac disease vs 27% (20 patients) femoral
disease. Stents were used in 46/71 iliac lesions (34 patients) and in 20/40 femoral lesions (16 patients). In the supervised
hospital-based exercise group, 68% (51 patients) had iliac disease vs 32% (24 patients) with femoral disease. There was a
non-significant difference in the adjusted 6- and 12-month EuroQol, rating scale, and SF36-physical functioning values
between the treatment groups. The gain in total mean QALYs accumulated during 12 months, adjusted for baseline
values, was not statistically different between the groups (mean difference revascularization versus exercise 0.01; 99% CI
0.05, 0.07; P .73). The total mean cumulative costs per patient was significantly higher in the revascularization group
(mean difference €2318; 99% CI €2130, € 2506; P < .001) and the incremental cost per QALY was 231 800 €/QALY
adjusted for the baseline variables. One-way sensitivity analysis demonstrated improved effectiveness after revasculariza-
tion (mean difference 0.03; CI 0.02, 0.05; P < .001), making the incremental costs 75 208 €/QALY.
Conclusion: In conclusion, there was no significant difference in effectiveness between endovascular revascularization
compared to supervised hospital-based exercise during 12-months follow-up, any gains with endovascular revasculariza-
tion found were non-significant, and endovascular revascularization costs more than the generally accepted threshold
willingness-to-pay value, which favors exercise. ( J Vasc Surg 2008;48:1472-80.)Intermittent claudication is the mildest manifestation
(ie, Rutherford category 1, 2, or 3) of peripheral arterial
disease (PAD), with a prevalence around 5% in men older
than 50 years.1,2 As the incidence of intermittent claudica-
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1472tion will increase over the next decades due to the aging
population in Western societies, the economic impact of
intermittent claudication is expected to be substantial.3
The treatment goal for intermittent claudication is to
improve health-related quality-of-life. The general consen-
sus is to initially treat with exercise training, but endovas-
cular revascularization is increasingly performed because of
its technical innovations, immediate success, and low risks
of periprocedural mortality and morbidity, which makes it
attractive for both the physician and the patient.4 In addi-
tion to effectiveness, however, one needs to consider costs
and cost-effectiveness. Initial hospital costs for endovascu-
lar revascularization are likely higher than those for exercise
training. Besides these initial hospital costs, the cost of
follow-ups are important to take into account, such as the
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re-interventions.
This randomized controlled trial (RCT) compared en-
dovascular revascularization vs supervised exercise training
as first-line treatment of intermittent claudication, with
regard to cost-effectiveness during 12-month follow-up.
METHODS
Study design and patients. The study was an RCT
comparing endovascular revascularization to supervised
Fig 1. Flow diagram of study (according to CONSORT
assignment to endovascular revascularization and supervi
received, including 6- and 12-months follow-up.hospital-based exercise in patients with symptoms of inter-mittent claudication (Rutherford category 1, 2, or 3). The
study was performed following good clinical practice and
was registered (ISRCTN 64443682).5 Data were analyzed
and reported according to CONSORT guidelines.6 Insti-
tutional review board approval was obtained and all pa-
tients gave written informed consent.
All patients referred to the Department of Vascular
Surgery with intermittent claudication from September
2002–September 2005 were considered for recruitment
(Fig 1). Inclusion criteria were: (1) Rutherford category 1,
ment). Diagram illustrates reasons for exclusion, random
ospital-based exercise training and the treatment actuallystate
sed h2, or 3 3 months; (2) maximum pain-free walking dis-
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index (ABI)0.9 at rest ABI with a decrease of0.15 after
the treadmill test; (4) vascular stenoses of 50% diameter
reduction at the iliac or femoro-popliteal level; (5) in-
formed consent. Exclusion criteria were: (1) abdominal
aortic aneurysm; (2) life-incapacitating cardiac disease
(NYHA classification III and higher (ie, patients had
marked limitation of physical activity, comfortable at rest,
but less than ordinary activity causes fatigue, palpitation, or
dyspnea);7 (3) multilevel disease, which would have made
multiple revascularization (endovascular and/or surgical)
procedures necessary (ie, same-side stenoses at both the
iliac and femoral levels, requiring multiple revascularization
procedures); (4) isolated tibial artery disease; (5) lesions
deemed unsuitable for revascularization (iliac or femoro-
popliteal TASC-type D and some TASC type-B/C le-
sions);8 (6) prior treatment for the same lesion (including
exercise training).
Indication for treatment and exclusion criteria were
assessed at the vascular conference by consensus between
the vascular surgeons and interventional radiologists. An
independent statistician prepared a computer-generated
randomization list with a block size of 16. Study personnel
dealing with bias-sensitive data were blinded to the as-
signed treatment and block size.
PROCEDURES
Endovascular revascularization was performed using a
10% oversized balloon (Powerflex or Opta-Pro; Cordis
Johnson & Johnson, Miami, Fla). For iliac revasculariza-
tion, the initial balloon angioplasty was considered techni-
cally successful if the pressure gradient across the treated
arterial segment was10 mm Hg at rest. If balloon dilata-
tion was inadequate, a 9 mm diameter, self-expanding,
nitinol stent (Luminexx, Bard, Tempe, Ariz) was placed.
For femoral revascularization, the decision to place an
additional 6-mm diameter, self-expanding, nitinol stent
was based on the post-balloon angioplasty angiogram.
Hospital-based exercise was conducted on a walking
treadmill for 30 minutes/session, twice weekly, during 24
weeks, which is consistent with a systematic review of the
literature of supervised exercise regimens9 and was consid-
ered the maximum attainable in our setting. Each session
was supervised by a vascular technologist and began at 3.5
km/hour without incline, and workload was increased
(speed or incline as tolerated) until a severe level of claudi-
cation pain was reached. The workload was lowered to 1
km/hour until the pain abated, and to avoid that patients
were walking with an ischemic leg the whole time. After the
pain had been abated, the patient resumed walking at
higher workload. This process was repeated for 30minutes.
In addition, all patients were instructed to walk at home for
at least 30minutes 3 times weekly. Feedback and evaluation
of these home-based exercise hours were also reported.
After the 24-week period, patients were advised to continue
exercise at home.
Before randomization, all patients underwent manage-
ment of risk-factors, including hypertension, serum glu-cose, cholesterol, lipid profile, and homocysteinemia (if age
50 years), and all were prescribed aspirin therapy (100
mg/day).
OUTCOMES
The outcomes were effectiveness expressed as mean
improvement of health-related quality-of-life and func-
tional capacity over the 12-month period and cumulative
12-month costs. Quality-of-life was assessed using a self-
administered questionnaire. Costs were assessed from the
societal perspective, according to national guidelines for
cost-analyses.10 In addition, clinical success was also as-
sessed but is reported separately in a manuscript focusing
on the clinical outcomes.
The questionnaire consisted of the EuroQol-5D (EQ-
5D) rating scale, and the dimension “physical functioning” of
the Medical Outcomes Study 36-Item Short Form Health
Survey (SF-36). The EQ-5D is a multi-attribute utility instru-
ment that assesses quality-of-life values from the societal per-
spective and classifies patients into a health-state.11 For each
health-state, a value was calculated using the Dutch scoring
algorithm, which was derived from the general population:12
0 equates to death and 100 equates to maximum health. The
rating scale required the respondent to rate their overall health
on a scale from 0-100, where 0 represents death and 100
perfect health.13 The SF-36 was developed to evaluate physi-
cal, social, and physical-role functioning of patients, and it
elicits their perceptions of their general health and well-being
in eight different health dimensions.14 “Physical functioning”
is most relevant to PAD, and we restricted this analysis to it.15
The SF-36 was valued on a 100-point scale: 0 means worst
health and 100 indicated maximum health. Quality-adjusted
life years (QALYs) accumulated during the 12-month fol-
low-up period were based on the EQ-5D values at baseline,
6-months, and 12-months. Functional capacity was expressed
as maximum pain-free walking distance and maximum walk-
ing distance andmeasured following treadmill walking (speed
3.5 km/hour, without a graded incline).
Costs (health care costs and non-health care costs) of all
relevant items used during the entire trial were collected.
Health care costs included costs of all therapeutic proce-
dures, personnel, materials, equipment, additional associ-
ated diagnostic or therapeutic procedures, and associated
mean hospital admissions during 12-month follow-up. Per-
sonnel costs were computed by multiplying time spent with
the mean wage rate of the appropriate personnel-category
and adding 37% Social Security.10 Costs of materials were
summed cost prices. Equipment costs were calculated as:
(time spent on a procedure)  (hourly cost). The annu-
itized hourly costs of equipment were summed with servic-
ing costs and divided by the proportion of total available
room time (33% of a 40-hour work-week for endovascular
revascularization and 80% of a 40-hour work-week for
supervised exercise).10
Non-health care costs included costs of supporting
departments, housing, overhead, transportation costs, and
patient time costs. The costs of supporting departments
were obtained from records of our financial department;
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assignable costs.10 Transportation costs included parking
costs and mean estimated gasoline costs. Patient-time costs
were (hourly wage rate)  (number of hours in-hospital).
The hourly wage rate was estimated with the published
mean hourly wage rate for Dutchmen andwomen given for
different age categories (25-44, 45-54, 55-64, 65). The
time required for treatment was based on the mean length
of hospitalization, which was estimated from the records of
patients undergoing revascularization (8 hours) and/or the
exercise program (30 minutes/session). In addition, time
invested in unsupervised exercise at home was reported and
included in the patient-time cost analysis. Productivity
losses were not included as most patients were retired and
among the patients who did work, no patient lost his/her
job due to claudication.
Costs were discounted at a rate of 3% per annum.16 All
costs are reported in 2005 euros using the consumer price
indices of the Central Bureau of Statistics, The Nether-
lands.17,18
Data analysis. Previous studies have shown that the
SF-36 dimension “physical functioning” was the most re-
sponsive for measuring changes in quality-of-life after ade-
quate treatment of patients with PAD.15,19,20 Based on
these studies, 40-50% of patients were expected to have a
substantial improvement of their symptoms after 6 months
as measured by the dimension “physical functioning” on
the SF-36. A percentage difference of 20-25% between the
treatment groups was considered clinically relevant.21 With
these assumptions, 68 patients were required in each trial
arm for a power of 80% and a 5% significance level. Antici-
pating a 5-10% loss to follow-up, we recruited 15 extra
patients.
Results were analyzed according to the intention-to-
treat principle: we analyzed all patients according to their
allocated intervention irrespective of cross-over to the other
strategy or completion of follow-up. The only patients
excluded from the analysis were those for whom no data
was available as they refused further participation immedi-
ately following randomization. In addition, results were
analyzed with imputation of mean values for quality-of-life
at 6- and 12-month follow-up for patients who died of
causes other than PAD and for patients who refused a
follow-up visit.22 There were no patients who died of PAD,
and there were no missing cost values.
QALY improvement accumulated during the 12-
month follow-up period was calculated per patient as the
integral under the EQ-5D graph as a function of time
adjusted for the baseline value. Since interpolating between
the baseline and 6-month value may underestimate the
integral under the EQ-5D, we imputed values at 1 week. In
patients with a clinical success at 1 week, the 1 week EQ-5D
value was assumed equal to the mean EQ-5D value in
patients with a clinical success at 6 months. In patients who
were negative for clinical success at 1 week, we used the
baseline EQ-5D value. In a one-way sensitivity analysis we
assumed that the EQ-5D value in the revascularization
group would increase immediately after the last interven-tion to the 6-month value (generating a larger integral
under the EQ-5D, which means a larger and more imme-
diate effect), whereas in the exercise group we interpolated
between the baseline value and the 6-month value to
account for the gradual improvement during the course of
the 24-week exercise program. In addition, we calculated
the incremental cost-effectiveness ratio as the difference in
mean cumulative total costs divided by the difference in
mean QALY improvements accumulated during 12
months for the revascularization group compared to the
exercise group.
To adjust outcomes for potential imbalances of baseline
values and characteristics between the treatment groups,
we adjusted for covariates using multivariable regression
analyses. We adjusted for baseline scores, age, gender,
diabetes mellitus, smoking, hypertension, hyperlipidemia,
and disease severity (mild/moderate claudication vs severe
claudication). The variables were selected based on the
TASC-II report and on clinical judgment.23
Significance of differences between group means was
assessed with the unpaired t test or the Mann-Whitney U
test, as appropriate, whereas significance of dichotomous
outcomes was assessed with the 2 test. To adjust for
multiple comparisons, a significance level of 0.01 (two-tailed)
was used. Ninety-nine percent confidence intervals of the
mean cost differences and the mean differences in QALY
improvement were calculated with the bootstrap resample
method drawing 100,000 samples.24 Cost-effectiveness out-
comes were combined in one outcome: net monetary bene-
fit25 expressed as the monetary equivalent of effectiveness,
which is QALY times the threshold willingness-to-pay
(50,000 €/QALY) minus the costs. We determined the
probability that revascularization would be cost-effective
compared to exercise for varying willingness-to-pay values
(acceptability curve).
In value of information analysis, we determined the
expected value of obtaining more information from future
research.26 The expected value of perfect information per
patient was calculated as27 the mean of the net monetary
benefit of the optimal treatment per bootstrap sample (ie,
the expected net monetary benefit with perfect informa-
tion) minus the mean net monetary benefit with current
information from the primary analysis. Next, we estimated
the population expected value of perfect information,
which was the total expected value of perfect information
per patient multiplied by the total number of patients that
could benefit from the decision (290,000 annually in the
European Union (E.U.) and 190,000 in the United States
(U.S.)28 over the lifetime of the technology (5 years)28
with a discount rate of 3% per year.
Calculations were performed with SPSS 14.0 for Win-
dows (SPSS Inc., Chicago, Ill), and R version 2.5 (R
Foundation, Vienna, Austria).
RESULTS
Patients. Fig 1 shows the flow diagram of patients
entering the RCT, including the actual treatments received
and patients who were lost to follow-up. One patient who
o be s
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lected, was excluded from the analysis. Thus, 150 patients
were analyzed for quality-of-life and costs (Fig 1). In the
revascularization group, 4 patients technically failed initial
treatment. Two were advised home-based exercise, and 2
underwent surgical intervention (Fig 1). The baseline char-
acteristics of the study participants did not differ signifi-
cantly between the groups (Table I). Ninety-two percent
(69 of 75) of revascularization patients responded to the
questionnaires at 6 months and 89% (67 of 75) at 12
months. Among exercise patients, 99% (74 of 75) responded
at 6 months, and 96% (72 of 75) at 12 months. During
follow-up, 10 patients in the revascularization group and 11
patients in the exercise group underwent additional treatment
(Table II). Eight patients in the exercise group underwent
endovascular revascularizationwhereas 3 patients in the revas-
cularization group started home-based exercise.
OUTCOMES
In both the revascularization group and the exercise
group improvement in the adjusted 6- and 12-months
Table I. Baseline characteristics of the study participants*
Endovascular Rev
(n 
Age (y) 65 (/
Male gender, % 44 (59)
Arterial hypertension, % 32 (43)
Diabetes mellitus, % 11 (16)
Hyperlipidemia, % 40 (53)
History of ischemic heart disease, % 14 (19)
Pulmonary disease, % 7 (9)
Osteoarthritis of the lower limb, % 7 (9)
Renal insufficiency, % 1(1)
History of cerebrovascular disease, % 8 (11)
Smoking, %
current 12 (16)
ever 40 (53)
never 23 (31)
Body mass index 26 (/
Ankle-brachial index
†
at rest 0.62 (/
after exercise 0.41 (/
Pain-free walking distance (m) 82 (/
Maximum walking distance (m) 174 (/
Rutherford classification
‡
, %
I & II 57 (76)
III 18 (24)
Iliac disease, % 73 (55)
Femoral disease, % 27 (20)
Quality of life
EuroQol-5D
§
0.66 (/
Rating scale

62 (/
SF-36 Physical functioning 42 (/
SF-36 Dimension scores  0-100 (worst-best) scale.
*Mean / standard deviation in parentheses, unless otherwise indicated.
†Minimum of right – left.
‡Most severe classification per person.
§EuroQol-5D with Dutch algorithm was used; EuroQol-5D value  0-1 (d
rating scale  0-100 (worst-best) scale.
**Considering multiple statistical tests, a P value of  .01 was considered tEuroQol, rating scale, and SF36 physical functioning wasdemonstrated, but the differences between the groups were
not statistically significant (Table III). Whereas in the en-
dovascularization group all quality-of-life measures showed
a non-significant decrease in quality of life from 6 to 12
months, in the exercise group there was an increase in two
of the three measures (Table III). After adjustment for
baseline variables, the QALY improvement accumulated
during 12-month follow-up was not significantly different
between the groups (mean difference 0.01; 99%CI,0.05,
0.07; P  0.73) (Table III). At 6- and 12-months, both
revascularization and exercise patients improved their maxi-
mum pain-free walking distance and their maximum walking
distance (Table III). After adjustment for the baseline vari-
ables, therewere no significant differences in functional capac-
ity between the two groups at 6- or 12-month follow-up.
After adjustment for the baseline variables, the total
mean cumulative costs per patient during 12 months were
higher following revascularization than following exercise
(mean difference €2,318; 99% CI, €2,130, € 2,506; P 
.001) and themean incremental cost-effectiveness ratio was
231,800 €/QALY (Table IV). The sensitivity analysis dem-
arization Hospital-based Exercise
(n  75) P value**
66 (/9) .34
39 (53) .62
28 (38) .87
15 (24) .83
38 (51)) .87
21 (28) .19
9 (12) .50
5 (6) .66
3 (4) .35
4 (5) .32
17 (23) .87
32 (43)
25 (34)
25 (/5) .88
8) 0.63 (/0.17) .62
2) 0.42 (/0.21) .60
104 (/65) .04
186 (/97) .62
57 (76) .87
18 (24) .87
68 (51) .47
32 (24) .47
0) 0.69 (/0.21) .22
65 (/18) .47
49 (/20) .11
maximum health) scale.
tatistically significant.ascul
75)
11)
4)
0.1
0.2
48)
76)
0.2
17)
26)
eath-onstrated a larger gain in effectiveness following revascular-
be st
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.001), making the incremental cost-effectiveness ratio
smaller (75,208 €/QALY) (Table IV). Combining QALYs
and costs using a willingness-to-pay of 50,000 €/QALY
resulted in a higher mean net monetary benefit per patient
for the exercise group (€6,891; 99% CI, 5,128, 8,656)
compared to the revascularization group (€3,639 99% CI,
2,214, 5,064). Using a willingness-to-pay value of 50,000
€/QALY, revascularization would be the optimal first-line
treatment in 5% of bootstrap samples (Fig 2a), whereas in
the sensitivity analysis this would be the case in 10% (Fig
2b). The total expected value of perfect information ex-
pressed in net monetary benefit was €30 per patient and the
population expected value of perfect information was €39
million for the E.U. and €26 million for the U.S (Table V).
DISCUSSION
In this prospective RCT, the cost-effectiveness of en-
Table II. Additional treatment during follow-up
Additional treatment
Endovas
0-6 months
Home-based exercise 3
Endovascular revascularization with or without
stent placement
Common iliac artery 0
Femoral artery 0
Surgical intervention
Aorto-bifurcation graft 2
Femoral-femoral cross-over graft 1
Femoro-popliteal bypass 0
Patch plasty of common femoral artery 2
Table III. Mean improvement in different measures of qu
differences between the groups (endovascular revasculariza
Mean score im
Endovascular
revascularization
(n  75)
EQ-5D 6 months
‡
0.16 (0.10, 0.21
EQ-5D 12 months 0.11 (0.04, 0.18
Quality-adjusted life years accumulated
during 12 months (0.15, 0.24
Maximum pain-free walking distance 6
months (m) 679 (519, 837)
Maximum pain-free walking distance 12
months (m) 806 (646, 960)
Maximum walking distance 6 months (m) 755 (600, 909)
Maximum walking distance 12 months (m) 826 (680, 970)
*Positive difference indicates endovascular revascularization has a better ou
outcome.
†Adjusted for baseline quality-of-life scores or functional capacity scores, ag
hyperlipidemia, and diabetes mellitus.
‡EuroQol-5D with Dutch algorithm was used; EuroQol-5D value  0-100
§Rating scale and SF-36 Dimension scores  0-100 (worst-best) scale.
Considering multiple statistical tests, a P -value of  .01 was considered todovascular revascularization was compared to supervisedhospital-based exercise in patients with intermittent claudi-
cation after 12-month follow-up. There was no significant
difference in the 6- and 12-month EuroQol rating scale,
SF36 physical functioning, and QALYs between the treat-
ment groups and revascularization was significantly more
expensive, which favors exercise. Furthermore, the small
gain achieved with endovascular revascularization was non-
significant and the incremental cost/QALY gained by re-
vascularization compared to exercise was higher than the
generally-accepted willingness-to-pay threshold of 50,000
€/QALY. The large population expected value of perfect
information suggests that a substantial investment in future
research would be justified.
Prior to the current RCT, there was no level-I evidence
with respect to the effectiveness and costs of treatment for
intermittent claudication. In the published literature about
intermittent claudication, one previous study compared
quality-of-life and costs for percutaneous transluminal an-
revascularization
 75)
Supervised hospital-based exercise
(n  75)
6-12 months (n) 0-6 months (n) 6-12 months (n)
0 0 0
1 2 3
1 2 1
0 1 0
0 0 0
0 2 0
0 0 0
of life and functional capacity compared to baseline and
compared to supervised hospital-based exercise*)
§
ement (99% CI)*
Adjusted mean difference
(99% CI)*
†
Adjusted
P-value

Hospital-based
exercise
(n75)
0.09 (0.03, 0.15) 0.02 (0.07, 0.10) .59
0.07 (0.02, 0.13) 0.02 (0.09, 0.12) .63
0.17 (0.14, 0.22) 0.01 (0.05, 0.07) .73
899 (743, 1054) 16 (32, 2) .02
943 (786, 1099) 24 (42, 91) .34
1138 (1006, 1270) 16 (60, 93) .58
1034 (896, 1170) 24 (42, 91) .34
; negative number indicates supervised hospital-based exercise has a better
der, severity of disease (mild/moderate vs severe), smoking, hypertension,
h-maximum health) scale.
atistically significant.cular
(n
(n)ality
tion
prov
)
)
)
tcome
e, gen
(deatgioplasty, bypass surgery, or exercise using a Markov deci-
be sta
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study showed that QALYs increased only slightly with
vascular interventions compared to exercise, and that any
small gain in QALYs that is obtained through vascular
intervention is done so at a high cost ($311,000/QALY).
The current study supports these findings and found a
similar incremental cost-effectiveness ratio (230,000
€/QALY  $330,000/QALY).
Revascularization has higher initial costs than exercise. Be-
sides thehigher initial costs,we also foundhigher follow-up costs
as revascularization patients had more surgical interventions
than exercise patients, who tended to get a (less-expensive)30
endovascular revascularization if secondary treatment was
needed. This difference in secondary treatment arose be-
cause three arterial lesions were not suitable for endovascu-
lar (re-)intervention after prior failure and because of sur-
geon preference in 2 patients. Whatever the treatment
considered, if the initial procedure failed, total costs during
12-month follow-up are 2- to 4-fold higher than if the
initial procedure was successful.30
Our study may have lacked power as it was designed to
demonstrate clinically-relevant differences, rather than
equivalences, in quality-of-life. The differences in the 6-
and 12-month quality-of-life results were small and non-
significant. Furthermore, it should be noted that quality-
of-life is a subjective outcome which may be influenced by
the perception of individual subjects. Patients in the exer-
Table IV. Total mean cumulative costs per patient during
and supervised hospital-based exercise
Endovascula
revascularizati
(n  75)
Procedure
Material costs € 1444
Personnel costs € 441
Equipment costs € 76
Associated admission costs € 217
Total mean cumulative procedure costs € 2178 (1949, 24
Patient
Transportation costs € 13
Productivity losses € 552
Total mean cumulative patient costs € 565 (519, 612
Follow-up
Associated outpatient visits and ABI
measurements € 86
Additional imaging costs € 65
Additional therapeutic costs € 657
Additional admission costs
†
€ 2578
Total mean cumulative follow-up costs € 3401 (865, 701
Total mean cumulative housing/supporting
departments/overhead costs € 793 (767, 818
Total mean cumulative costs € 7031 (4522, 10
ABI, Ankle brachial index; 95% CI, 95% confidence interval determined wit
*Adjusted for age, gender, severity of disease (mild/moderate vs severe), sm
†In the endovascular revascularization group, the additional admission c
revascularizations (n  2). In the supervised hospital-based exercise group
endovascular revascularizations (n  8).
‡Considering multiple statistical tests, a P value of  .01 was considered tocise group may have underestimated their quality-of-lifesince improvement in symptoms occurs slowly during an
exercise program andmay, therefore, have been less notice-
able. Conversely, the revascularization group may have
overestimated their quality-of-life since their improvement
after treatment was immediate and, therefore, would have
contrasted with the pre-intervention state. This may indi-
cate that the difference in quality-of-life between the treat-
ment groups may in fact have been in favor of exercise.
Furthermore, we had limited follow-up time-points and
our 1-week quality-of-life value was based on the clinical
success rather than a direct measurement of quality-of-life.
In a sensitivity analysis using a fairly extreme assumption
favoring revascularization, however, the conclusions re-
mained the same. Another limitation could be that our
study took place in a single center and with adherence to
strict in- and exclusion criteria. Consequently, there were
patients excluded based on anatomic reasons and consid-
ered to be unsuitable for revascularization. In clinical prac-
tice some patients may be good candidates for exercise
therapy and poor candidates for revascularization and vice
versa, which affects the generalizability of our results and
emphasizes the importance of patient-tailored decision
making. The advantage of our single center study and
adhering to strict in- and exclusion criteria is the homoge-
neous group of study participants, as illustrated by the
baseline characteristics. Another limitation of our study is
that bias towards exercise may have occurred in patients
onths of follow-up after endovascular revascularization
Hospital-based
exercise
(n  75)
Adjusted mean
difference
(99% CI)*
Adjusted
P-value
‡
€ 1
€ 433
€ 51
€ 0
€ 485 (454, 515) € 1035 (903, 1167) .001
€ 164
€ 941
€ 1104 (1021, 1189) € 504 (463, 546) .001
€ 0
€ 92
€ 532
€ 339
€ 958 (333, 1769) € 205 (187, 223) .001
€ 207 (203, 211) € 586 (560, 611) .001
€ 2771 (2158, 3591) € 2318 (2130, 2506) .001
bootstrap resample method.
g, hypertension, hyperlipidemia, and diabetes mellitus.
ere due to surgical interventions (n  5) and secondary endovascular
additional admission costs were due to surgical interventions (n  3) and
tistically significant.12 m
r
on
19)
)
8)
)
556)
h the
okin
osts w
, thewith bilateral symptoms, as walking inherently treats both
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Volume 48, Number 6 Spronk et al 1479limbs. To be consistent, patients with bilateral symptomatic
lesions in the endovascular revascularization group were
treated on both sides. The severity of ipsilateral symptoms
at baseline, however, may have disguised latent contralat-
eral symptoms in some patients. After endovascular revas-
cularization, increased mobility would encourage the dis-
covery of the latent contralateral symptoms. Since
peripheral arterial disease is a two-limb problem we chose
for a patient-based approach to treatment and analysis of
the trial results.
As with every randomized trial, we could only evaluate
a limited number of strategies. In addition to revasculariza-
tion and exercise training, other treatment strategies are of
Fig 2. a, Cost-effectiveness acceptability curve for revasculariza-
tion versus exercise for the baseline analysis. b, Cost-effectiveness
acceptability curve for revascularization versus exercise for the
sensitivity analysis.interest, for example, optimal medical treatment in combi-nation with home-based exercise or optimal medical treat-
ment combined with angioplasty, which have been com-
pared in a previous RCT.31 Other interesting treatment
arms could be revascularization plus supervised exercise
training or revascularization plus pharmacologic therapy.
Since the recently performed RCT costs less than €1million
and our estimated population expected value of perfect
information was well over €1million for the E.U. or U.S.
populations, further clinical studies in this area are expected
to be worth the cost.
CONCLUSIONS
In conclusion, there was no significant difference in
effectiveness between endovascular revascularization com-
pared to supervised hospital-based exercise during 12-
month follow-up, any gains with endovascular revascular-
ization found were non-significant, and endovascular
revascularization costs more than the generally accepted
threshold willingness-to-pay value, which favors exercise.
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